Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial

BACKGROUND: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, pertuzumab is not available to all patients due to cost. The optimal neoadjuvant chemotherapy for HER2-positive bre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hong-Fei, Wu, Zhiyong, Lin, Ying, Song, Xiang-Yang, Cao, Yin, Chen, Qian-Jun, Zhang, Gangling, Fu, Peifen, Liu, Zhenzhen, Zhang, Liu-Lu, Yang, Ci-Qiu, Yang, Mei, Zhu, Teng, Ji, Fei, Li, Jie-Qing, Cheng, Min-Yi, Wang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064510/
https://www.ncbi.nlm.nih.gov/pubmed/33959195
http://dx.doi.org/10.1177/17588359211009003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064510/
https://www.ncbi.nlm.nih.gov/pubmed/33959195
http://dx.doi.org/10.1177/17588359211009003

Ejemplares similares